RxDoctor Payments Data

Heather Ballantyne, APRN

Family · Las Vegas, NVNPI 1619532876

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 36 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$354
  • AstraZeneca$146
  • Johnson & Johnson$141
  • Pfizer$140
  • Medtronic$132
  • Boehringer Ingelheim$118
  • plus $294 from 9 others

What the payments were for

  • Food & beverage$1,30999%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,325 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$16,212
Medicare patients
102
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$543,690
EntrestoSacubitril/Valsartan151$230,962
JardianceEmpagliflozin74$95,261
XareltoRivaroxaban74$78,828
Repatha SureclickEvolocumab40$45,652
FarxigaDapagliflozin Propanediol11$10,976
Metoprolol Succinate363$3,576
Atorvastatin Calcium358$2,745
Ranolazine ErRanolazine23$2,453
Midodrine Hcl23$2,271
Valsartan68$1,855
Rosuvastatin Calcium135$1,322
Carvedilol202$1,255
ClopidogrelClopidogrel Bisulfate137$1,219
Potassium Chloride110$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$543,690384 claims
NovartisEntresto$354$230,962151 claims
Boehringer IngelheimJardiance$118$95,26174 claims
Johnson & JohnsonXarelto$141$78,82874 claims
AstraZenecaFarxiga$146$10,97611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →